Read the latest research on Alzheimer's disease. Learn about Alzheimer's symptoms such as memory loss and senile dementia. Find out about Alzheimer's stages, causes and new treatments.
Updated: 16 min 19 sec ago
The pandemic has exacerbated isolation and fears for one very vulnerable group of Americans: the 4.3 million older adults with cognitive impairment who live alone.
Using a blood test, a research team has predicted the risk of Alzheimer's disease in people who were clinically diagnosed as not having Alzheimer's disease but who perceived themselves as cognitively impaired (Subjective Cognitive Declined, SCD). The researchers analyzed blood samples from an SCD cohort. Using a newly developed test, they identified all 22 subjects at study entry who developed Alzheimer's dementia, thus the clinical symptoms, within six years.
As they age, people with diabetes are more likely to develop Alzheimer's disease and other cognitive disorders than are people without diabetes. Scientists now have shown that routine eye imaging can identify changes in the retina that may be associated with cognitive disorders in older people with type 1 diabetes. These results may open up a relatively easy method for early detection of cognitive decline in this population.
Researchers have been trying to figure out what regulates molecular circadian clocks, in search of new insights into diseases like Alzheimer's, cancer and diabetes. Until now, that research has focused on what is known as clock genes. But new research reveals the discovery of a new cog in the circadian clock - a genome-wide regulatory layer made up of small chains of non-coding nucleotides known as micro RNAS (miRNAs).
Scientists have announced a significant advance in our understanding of an early onset form of dementia that may also progress our understanding of conditions such as Alzheimer's disease. Adult onset Leukoencephalopathy with axonal Spheroids and Pigmented glia (ALSP) is an ultra-rare condition that manifests initially with psychiatric and behavioural changes in patients followed by a rapid progression of dementia in the third or fourth decade of life.
A new study found a specific Alzheimer's treatment is effective in male and not female mice, providing a window into the biology of the disease and the effectiveness of targeted treatments.